Bevacizumab with chemotherapy in patients withKRASwild-type metastatic colorectal cancer: Czech registry data

    loading  Checking for direct PDF access through Ovid

Abstract

Aim:

This retrospective analysis investigated the effectiveness of combination therapy with bevacizumab and chemotherapy in the first-line treatment of patients withKRASwild-type metastatic colorectal cancer.

Patients & methods:

Patients withKRASwild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled. Overall survival and progression-free survival were the main effectiveness end points.

Results:

A total of 981 patients were enrolled. Median progression-free survival was 11.3 months (95% CI: 10.7–11.8) and median overall survival was 28.4 months (95% CI: 26.2–30.6). The most common adverse events were thromboembolic disease (4%) and hypertension (3.5%).

Conclusion:

This retrospective analysis shows the effectiveness of bevacizumab with chemotherapy in patients withKRASwild-type metastatic colorectal cancer.

Related Topics

    loading  Loading Related Articles